SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Apple Turns 50: From Garage Startup to AI Crossroads 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2017 -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer, will present at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017 at 9:30 AM Pacific Standard Time.
The live webcast will be accessible at http://investor.fiveprime.com/events.cfm or directly at http://jpmorgan.metameetings.com/confbook/healthcare17/directlink?p=22561. Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit www.fiveprime.com.
CONTACT: Heather Rowe, Investor Relations 415-365-5737 [email protected]
